动脉粥样硬化疫苗的机遇:从小鼠到人类
动脉粥样硬化是心血管疾病的主要病因和全球头号死因,其发病涉及代谢与免疫的复杂交互。他汀等降脂药物虽能降低心血管风险,但仍有显著的残余炎症风险。本综述讨论了人类动脉粥样硬化疫苗的现状与机遇,涵盖免疫调节干预、免疫靶点、动物模型免疫策略、已开展和正在进行的临床试验以及优化人类疫苗接种的策略。
要点
- 动脉粥样硬化发病涉及代谢与免疫的复杂交互,他汀降脂后仍存在显著残余炎症风险。
- 宿主介导的抗原特异性适应性免疫应答影响动脉粥样硬化多个阶段,起保护或促动脉粥样硬化作用。
- 疫苗是有望诱导保护性适应性免疫的高效、持久且相对廉价的方法。
核心结论
- 疫苗接种是有望为动脉粥样硬化患者诱导保护性适应性免疫的高效、持久且相对廉价的方法。
- 增强抗动脉粥样硬化体液免疫和T调节细胞应答的策略正成为降低残余炎症风险的新兴预防或治疗策略。
研究设计与样本
- 综述,讨论人类动脉粥样硬化疫苗的现状与机遇,涵盖免疫调节干预、免疫靶点、动物模型免疫策略、临床试验和优化接种策略。
主要发现
- 实验模型和临床研究的充分证据已确立炎症和免疫效应机制在动脉粥样硬化发病中的作用。
- 宿主介导的抗原特异性适应性免疫应答影响动脉粥样硬化多个阶段,起保护或促动脉粥样硬化作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atherosclerosis, the major underlying cause of cardiovascular diseases (CVD), is the number one killer globally. The disease pathogenesis involves a complex interplay between metabolic and immune components. Although lipid-lowering drugs such as statins curb the risks associated with CVD, significant residual inflammatory risk remains. Substantial evidence from experimental models and clinical studies has established the role of inflammation and immune effector mechanisms in the pathogenesis of atherosclerosis. Several stages of the disease are affected by host-mediated antigen-specific adaptive immune responses that play either protective or proatherogenic roles. Therefore, strategies to boost an anti-atherogenic humoral and T regulatory cell response are emerging as preventative or therapeutic strategies to lowering inflammatory residual risks. Vaccination holds promise as an efficient, durable and relatively inexpensive approach to induce protective adaptive immunity in atherosclerotic patients. In this review, we discuss the status and opportunities for a human atherosclerosis vaccine. We describe (1) some of the immunomodulatory therapeutic interventions tested in atherosclerosis (2) the immune targets identified in pre-clinical and clinical investigations (3) immunization strategies evaluated in animal models (4) past and ongoing clinical trials to examine the safety and efficacy of human atherosclerosis vaccines and (5) strategies to improve and optimize vaccination in humans (antigen selection, formulation, dose and delivery).
引用
- Roy P, Ali AJ, Kobiyama K, et al. Opportunities for an atherosclerosis vaccine: From mice to humans. Vaccine. 2020. PMID: 31964554. doi:10.1016/j.vaccine.2019.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。